NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Entrada Therapeutics, Inc. (TRDA) Stock Analysis

Entrada Therapeutics, Inc. (TRDA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

TRDA

$4.65

−$0.34 (−6.81%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TRDA with… →

TRDA Key Statistics

As of Oct 21, 2026
Trading
Open
$5.02
Previous Close
$4.99
Day's Range
4.60–5.04
52-Week Range
4.11–16.45
Volume
323.80K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.24
Valuation
Market Cap
$181.06M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
38.64
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.96
Financials (FY)
Revenue (FY)
$25.42M−87.94%
Net Income (FY)
−$143.75M−319.04%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
38.94M
1-Year Return
−26.89%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
356.72K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, TRDA closed at $4.65, −26.89% over 1 year.

Entrada Therapeutics, Inc. (TRDA) has a market capitalization of $181.06M.

In fiscal 2025, TRDA reported revenue of $25.42M.

TRDA Stock Return by Calendar Year

Entrada Therapeutics, Inc. (TRDA) return since Oct 2021: what $10,000 became

1 year
$10,000 $7,311
−26.89%
5 years
$10,000 $1,942
−80.58%

If you had invested $10,000 in Entrada Therapeutics, Inc. (TRDA) at the close on October 29, 2021, the earliest close on record here, it would have been worth $1,942 at the close on October 21, 2026: −80.58% in total, −27.95% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−54.77%
2025−40.54%
2024+14.58%
2023+11.61%
2022−21.03%
2021 (partial year)−28.52%

As of October 21, 2026.

TRDA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$25.42M−$143.75M−565.5%
2024$210.78M$65.63M31.1%
2023$129.01M−$6.69M−5.2%
2022$0.00−$94.62M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$25.42M—−$157.90M−$143.75M−565.5%
2024$210.78M—$47.01M$65.63M31.1%
2023$129.01M—−$3.16M−$6.69M−5.2%
2022$0.00—−$97.25M−$94.62M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

TRDA Valuation vs Biotechnology Median

Median of 608 stocks
MetricTRDABiotechnology medianvs median
P/S ratio38.6413.30191% above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 11 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Entrada Therapeutics, Inc. (TRDA) at $181.06M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 152 employees.

The 52-week range on file runs from $4.11 to $16.45. TRDA last closed at $4.65 on October 21, 2026. That is −$0.34 (−6.81%) against the previous close. The latest close sits 13.17% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $25.42M. Against the prior fiscal year total of $210.78M, that is a change of −87.94%. The same year closed with a net loss of $143.75M. Trailing earnings per share are −3.96.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $25.42M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 38.64 times revenue. On price-to-sales that is 190.54% above the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

The trailing one-year total return is −26.89%. Across 5 years the annualized return works out at −27.95%. Beta against the wider market is reported at −0.24. Daily returns over the trailing 5 years annualize to a volatility of 88.76%.

Growth & Income

No dividend is on file for TRDA.

2026 is still running; the total return is −54.77% year to date. The strongest complete calendar year on file is 2024 at +14.58%; the weakest is 2025 at −40.54%. Of the 4 complete calendar years on file, 2 finished higher.

Peer Comparison

Entrada Therapeutics, Inc. (TRDA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Entrada Therapeutics, Inc. TRDA $181.06M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Entrada Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Entrada Therapeutics, Inc.

Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Visit website →